FDA Approves Dupilumab for Children Aged 6 to 11 With Moderate to Severe Asthma

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for osteoporosis and bone loss in various patient populations.

Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1.

Several rare disease patient populations received their first-ever FDA-approved drug since Rare Disease Day last year, signifying progress in closing treatment gaps for rare disease.

An extensive library of physical activity resources will better support the different needs, capabilities, and considerations of patients with rheumatoid arthritis (RA), according to the researchers.

The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of Parkinson disease.

With 2 new self-administration methods, patients living with generalized myasthenia gravis can be more empowered to manage their treatment with greater independence and control.